NICE does not recommend Lynparza ( olaparib) in preliminary assessment for ovarian cancer- AstraZeneca
NICE (The National Institute for Care and Clinical Excellence) in the UK has issued a preliminary assessment not to recommend Lynparza (olaparib) from AstraZeneca for treatment of relapsed, platinum sensitive ovarian cancer, fallopian tube or peritoneal cancer. NICE rejected evidence from a sub group analysis of Study 19 and the calculation of progression free survival and noted that overall survival data were immature.The committee also considered that AstraZeneca's cost-effectiveness analysis excluded the costs of testing for a BRCA mutation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.